skip to Global Navigation Bar skip to main content

homeHome > About Us > Recruitment > News


News Content
Daewoong Pharmaceutical’s ‘Nabota’ secured application to blepharospasm.
Date 2019-06-24 Hit 1998
News List
Prev Daewoong Pharmaceutical initiates development of new medication for hearing impairment (First in Class) with Yonsei University based on the ion channel platform technology.
Next A global symposium pays attention to Nav 1.7 Chronic Pain Treatment, DWP17061.